Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited Fundamental Analysis
Dr. Agarwal's Health Care Limited (AGARWALEYE.NS) shows weak financial fundamentals with a PE ratio of 104.32, profit margin of 6.38%, and ROE of 6.92%. The company generates $19.9B in annual revenue with strong year-over-year growth of 28.44%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze AGARWALEYE.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakAGARWALEYE.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakAGARWALEYE.NS trades at a premium to fair value.
Growth Score
ModerateAGARWALEYE.NS shows steady but slowing expansion.
Financial Health Score
ExcellentAGARWALEYE.NS maintains a strong and stable balance sheet.
Profitability Score
WeakAGARWALEYE.NS struggles to sustain strong margins.
Key Financial Metrics
Is AGARWALEYE.NS Expensive or Cheap?
P/E Ratio
AGARWALEYE.NS trades at 104.32 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, AGARWALEYE.NS's PEG of 11.23 indicates potential overvaluation.
Price to Book
The market values Dr. Agarwal's Health Care Limited at 6.81 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 21.27 times EBITDA. This signals the market has high growth expectations.
How Well Does AGARWALEYE.NS Make Money?
Net Profit Margin
For every $100 in sales, Dr. Agarwal's Health Care Limited keeps $6.38 as profit after all expenses.
Operating Margin
Core operations generate 20.37 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.92 in profit for every $100 of shareholder equity.
ROA
Dr. Agarwal's Health Care Limited generates $3.33 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Dr. Agarwal's Health Care Limited produces operating cash flow of $2.63B, showing steady but balanced cash generation.
Free Cash Flow
Dr. Agarwal's Health Care Limited generates weak or negative free cash flow of $497.32M, restricting financial flexibility.
FCF Per Share
Each share generates $1.57 in free cash annually.
FCF Yield
AGARWALEYE.NS converts 0.37% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
104.32
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
11.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.81
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.69
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.51
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.43
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How AGARWALEYE.NS Stacks Against Its Sector Peers
| Metric | AGARWALEYE.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 104.32 | 28.45 | Worse (Expensive) |
| ROE | 6.92% | 763.00% | Weak |
| Net Margin | 6.38% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.51 | 0.34 | Weak (High Leverage) |
| Current Ratio | 1.43 | 2795.60 | Neutral |
| ROA | 3.33% | -16588.00% (disorted) | Weak |
AGARWALEYE.NS outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Dr. Agarwal's Health Care Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
276.86%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
256.13%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
246.89%
Industry Style: Defensive, Growth, Innovation
High Growth